Pain Management · Chronic Low Back Pain
This clinical trial compares the iovera° system to radiofrequency ablation, a standard treatment for chronic low back pain. The results could significantly influence treatment preferences and market dynamics in pain management, impacting Pacira Pharmaceuticals' competitive positioning.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/21/2026, 6:30:34 PM
Assessment confidence: 63% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
This clinical trial compares the iovera° system to radiofrequency ablation, a standard treatment for chronic low back pain. The results could significantly influence treatment preferences and market dynamics in pain management, impacting Pacira Pharmaceuticals' competitive positioning. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 4 ranked evidence items (2 high-relevance).
If iovera° proves superior, it could enhance Pacira Pharmaceuticals' position in the pain management market and influence treatment guidelines. The strongest clinical anchor is Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management (ClinicalTrials.gov), sub-indication match (pain). In pain, 2 regulatory and 0 competitive items passed relevance filtering for Pacira Pharmaceuticals.
The most relevant competitive pressure comes from This study may provide insights into the effectiveness of cryoneurolysis compared to the established radiofrequency ablation, potentially impacting treatment preferences and market dynamics..
Regulatory risk is concentrated around FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose (FDA). Sub-indication match (pain). The trial's outcomes are unlikely to directly influence regulatory approvals but may inform future clinical guidelines and practices.
FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
FDAhigh relevance
Sub-indication match (pain)
FDA document
View sourceFDA Public Meeting: FDA-Led Patient-Focused Drug Development Meeting for Nonhealing Chronic Wounds - 08/25/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View sourceClinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View sourceA Prospective Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Low Back Pain
ClinicalTrials.govmedium relevance
Entity match (pacira pharmaceuticals)
FDA document
View sourceEvaluation of the Effectiveness of Physical Therapy for Low Back Pain According to Magnetic Resonance Imaging Findings
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceLow Dose Naltrexone Therapy for Complex Regional Pain Syndrome
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceLeft Atrial and Left Ventricular Structural and Functional Evaluation by CCTA for Predicting Post-Ablation Outcomes in Patients With Atrial Fibrillation
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceCryoneurolysis for Painful Diabetic Neuropathy of the Foot
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceRavulizumab Shows Promise in Reducing Delayed Graft Function in Kidney Transplant Patients
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEffects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceComparative efficacy, recovery, and pigmentary safety of radiofrequency microneedling and fractional carbon dioxide laser for facial atrophic acne scars: a prospective randomized split-face trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceDo subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThis clinical trial compares the iovera° system to radiofrequency ablation, a standard treatment for chronic low back pain. The results could significantly influence treatment preferences and market dynamics in pain management, impacting Pacira Pharmaceuticals' competitive positioning.
If the iovera° system is proven more effective, it could lead to increased market share for Pacira Pharmaceuticals and shift treatment guidelines, potentially affecting revenue streams.
The trial's outcomes are unlikely to directly influence regulatory approvals but may inform future clinical guidelines and practices.
Monitor trial results and participant outcomes over the 14-month study period for potential shifts in clinical practice.
Track for follow-up milestones; no immediate action required.